Previous work implicated activation of the signal transducer and activator of transcription (STAT)3 downstream of the epidermal growth factor receptor (EGFR) in the malignant phenotype of squamous carcinoma cells (SCC). Here, we show that EGFR-dependent STAT3 activation is restricted to malignant keratinocytes. Specifically, constitutive and epidermal growth factor-induced phosphorylation of STAT3 on Y705 was observed only in SCC but not in either immortalized (HaCaT) or normal keratinocyte strains. Furthermore, STAT3 activation as determined by DNA binding assays was restricted to SCC and dependent on EGFR activation. Forced expression of EGFR in immortalized keratinocytes (HaCaT cells) was associated with enhanced EGFR activation but not STAT3-Y705 phosphorylation. EGFR-dependent activation of mitogenactivated protein kinase (MAPK) kinase 1 negatively regulated STAT3-Y705 phosphorylation in normal and malignant keratinocytes. Together, these results underscore that EGFR activation is required but not sufficient for STAT3 activation to occur in malignant keratinocytes. They also highlight complex regulation of STAT3 phosphorylation through EGFR activation including negative regulation via the MAPK kinase/MAPK signaling pathway.
INTRODUCTION
Activation of the epidermal growth factor receptor (EGFR) contributes to multiple aspects of epithelial cell biology relevant to malignant transformation. These include proliferation, migration, and invasion, and modulation of differentiation. Only recently has it become apparent that the EGFR also contributes to survival of epithelial cells including normal and malignant human keratinocytes (1) (2) (3) . If the EGFR is blocked, normal keratinocytes are significantly more susceptible to induction of apoptotic death by cellular stressors including UVB radiation (4) and matrix detachment (1, 5) . Other members of the EGFR family, notably erbB2, serve similar functions relevant to epithelial cell survival (6 -10) . We have identified one intracellular target of EGFR activation that supports keratinocyte survival (11, 12) . Specifically, EGFR activation through endogenous and exogenous ligands is associated with up-regulation of Bcl-x L , an antiapoptotic member of the Bcl-2 protein family. By contrast, expression of the proapoptotic Bcl-2 family members Bad, Bak, and Bax is not affected by EGFR activation. Thus, EGFR blockade is associated with a proapoptotic bias in the balance of pro-and antiapoptotic Bcl-2 family members. Similar results have since been reported by several other groups (2, 13, 14) .
One objective of our previous work was to understand which signaling pathway(s) lead from the EGFR to enhanced cell survival through higher levels of Bcl-x L expression. These studies demonstrated that EGFR-dependent signals relevant to keratinocyte survival and Bcl-x L expression are channeled in part through the mitogenactivated protein kinase (MAPK) kinase (MEK)/MAPK pathway (15) . EGFR-dependent MEK/MAPK activation additionally enhances epithelial cell survival by phosphorylation and functional inactivation of the proapoptotic Bcl-2 family member Bad (16) . In addition to MEK/ MAPK, activation of the signal transducer and activator of transcription (STAT)3 has been implicated in epithelial cell survival and Bclx L expression. STAT3 supports oncogenic transformation of mouse fibroblasts (17, 18) and survival of human squamous carcinoma cells (SCC), at least in part through up-regulation of Bcl-x L (19) . Conversely, EGFR blockade down-regulates STAT3 phosphorylation and DNA binding in some SCC lines consistent with EGFR-dependent regulation of STAT3 activity in this cell system. However, in immortalized keratinocytes, EGFR activation had no apparent effect on STAT3 phosphorylation and, moreover, inhibition of STAT activity by inducible expression of dominant-negative STAT3 constructs had no effect on Bcl-x L expression in these cells (5) .
Collectively, these previous observations raised the issue of whether EGFR-dependent STAT3 activation and its sequelae were restricted to malignant keratinocytes. The present study addresses this question by using normal human keratinocyte cultures, an immortalized keratinocyte line (HaCaT), and a panel of SCC lines exhibiting different levels of EGFR expression and activation states. We demonstrate that: (a) STAT3 phosphorylation on Y705 is a tumor-associated phenomenon in squamous carcinoma cells in vitro; (b) STAT3 phosphorylation on Y705 occurs through EGFR-dependent and -independent pathways in malignant cells; (c) overexpression of the EGFR is not sufficient for STAT3 phosphorylation in immortalized keratinocytes (HaCaT); and (d) DNA binding of activated STAT3 is restricted to malignant tumor cells and strictly dependent on EGFR activation. We conclude that STAT3 activation in normal and malignant keratinocytes is a tumor-associated phenomenon linked to deregulated EGFR signaling.
MATERIALS AND METHODS
Reagents and Cells. Properties of the EGFR antagonistic mAb425 have been described earlier (20, 21) . Inhibitors to MEK1 (U0126), phosphatidylinositol 3Ј-kinase (LY294002), SRC-kinases (PP1 and PP2), and the tyrphostins AG490 and AG1478 were purchased from Calbiochem-Novabiochem (San Diego, CA). Rabbit polyclonal antibodies to EGFR were from Santa Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling/NEB (Beverly, MA), and to ␤-actin from Amersham Biosciences (Piscataway, NJ). Antibodies to signal transduction components (STAT3, phospho-STAT3, p42/44 MAPK, and phospho-p42/44 MAPK) were from Cell Signaling Technology or Santa Cruz Biotechnology. Hemagglutinin tag antibodies were from Covance (Richmond, CA). Antiphosphotyrosine antibody PY20 was from Transduction Laboratories (San Diego, CA).
Normal foreskin keratinocytes were initiated and maintained in culture as described earlier (22) . Head and neck carcinoma cell lines SCC 9 and SCC 12 derived from facial skin were a kind gift from Dr. Jim G. Rheinwald. Head and neck carcinoma cell lines FaDu and Det562 were from the American Type Culture Collection (Rockville, MD). A431 cells were derived from a vulval SCC and originally provided by Dr. Ira Pastan (National Cancer Institute, NIH, Bethesda, MD). Immortalized keratinocytes (HaCaT cells) were from Dr. Norbert Fusenig (23) . HaCaT, SCC 9, SCC 12, FaDu, A431, and Det562 cells were maintained in W489 medium (24) supplemented with 2% FCS. For experiments, all of the cell lines were seeded at subconfluency in either complete MCDB medium (12) for primary keratinocyte cultures or W489 supplemented with 2% FCS for HaCaT cells and SCC lines. After attachment, medium was replaced with MCDB base medium (12) supplemented with growth factors and inhibitors of signal transduction components as indicated. Inhibitors were diluted from DMSO stocks directly into the culture medium. The DMSO concentration was adjusted to Ͻ0.5% in all of the conditions including controls. After 48 h cells were harvested for analysis.
cDNA Constructs and Transfections. A plasmid containing dominantnegative MEK1 (MKK1-8E) was cloned into pCEPTetP and transfected into HaCaT cells expressing tTA as described previously (15) . This system allows transgene induction by removal of tetracycline from culture medium (25) . Similarly, dominant-negative STAT3D and STAT3F were cloned into pCEPTetP and transfected into HaCaT-tTA1 cells as described previously (15) . The full-length EGFR cDNA was cloned into the pIRESpuro2 vector (Clontech, Palo Alto, CA) followed by stable transfection into HaCaT cells. Transfections were performed using Fugene 6 (Roche Molecular Biochemicals, Indianapolis, IN). Briefly, cells were seeded at a density of ϳ5 ϫ 10 3 /cm 2 in W 489 medium supplemented with 2% FCS and allowed to attach overnight. The next day transfections were performed using 0.5 g DNA and 1.7-2.0 l Fugene 6 per 10 5 cells following the manufacturer's protocol. Selection was started 48 -72 h after transfection in W489 medium supplemented with 2% FCS and puromycin at 1 g/ml (Sigma-Aldrich, St. Louis, MO).
Immunoprecipitation and Immunoblot Analyses. Samples for immunoprecipitation were collected by washing adherent cells once in ice-cold PBS followed by scraping into cold lysis buffer [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.0 mM EGTA, 1.0 mM EDTA, 10% glycerol, 1.0% Triton-X-100, 50 mM NaF, 10 mM Na4P2O7 containing freshly added protease inhibitors (Complete protease inhibitor mixture; Roche Molecular Biochemicals), 1 mM phenylmethylsulfonyl fluoride, and 1 mM Na3VO4]. After lysis for 20 min on ice, cell extracts were centrifuged at 15,000 ϫ g and supernatants stored at 70°C until further use. Protein content was determined using the BCA method (Pierce Chemical Co., Rockford, IL). Equal amounts of protein were precleared with 20 l Protein A/G Plus agarose (Santa Cruz Biotechnology) for 1 h at 4°C. Precleared lysates were then mixed with 2.0 g of primary rabbit EGFR antibody (Santa Cruz Biotechnology) and 20 l protein A/G Plus agarose and incubated overnight at 4°C. Precipitates were washed four times with lysis buffer, solubilized in 1ϫ reducing Laemmli buffer [62.5 mM Tris-Cl (pH 6.8), 1% SDS, 10% glycerol, 0.5 M 2-mercaptoethanol, or 0.1 M dithiothreitol], boiled for 3-5 min, and then subjected to SDS-PAGE followed by Western blot as described below.
Samples for Western blots were collected by washing cells once in cold PBS and lysis in Laemmli buffer followed by boiling for 3-5 min. Equal amounts of protein were separated by SDS-PAGE under reducing conditions and blotted onto nitrocellulose membranes (Millipore). Membranes were blocked using 5% dry milk in PBS or 5% dry milk, 0.05% Tween 20 (Sigma Aldrich) in Tris-buffered saline, and then incubated with primary antibodies in PBS or 5% BSA, 0.05% Tween 20 in Tris-buffered saline, followed by incubation in dilutions of horseradish peroxidase-conjugated secondary antibodies in the same buffers. After antibody incubations, blot membranes were washed in 0.5% Tween 20 in Tris-buffered saline. Signals were visualized by chemiluminescence using reagents from Pierce Chemical Co. according to the manufacturer's instructions. After detection, blots were washed and stripped using Restore Western Blot Stripping Buffer (Pierce Chemical Co.) and used for additional antibody incubations.
Electrophoretic Mobility Shift Assays. Cells were starved for 14 h in growth factor-free medium and then stimulated with epidermal growth factor (EGF) for 15 min. Whole cell lysates were prepared from control and EGFtreated cells. Briefly, after washing twice with PBS, cells were harvested in 1 ml of PBS and recovered by centrifugation. Cells were resuspended in twice the pellet volume using high salt buffer [20 mm HEPES (pH 7.9), 20 mm NaF, 1 mm Na 3 VO 4 , 1 mm EGTA, 1 mm EDTA, 1 mm DTT, 400 mm NaCl, 20% glycerol, 0.1% Triton X-100, 1 mm phenylmethylsulfonyl fluoride, and 1 g/ml leupeptin] and were kept for 30 min at 4°C under vigorous agitation. The lysates were centrifuged at 15,000 ϫ g for 20 min at 4°C, and protein concentrations of the clarified lysates were determined by Bradford assay. DNA binding was performed by adding 15-20 g of protein lysates to 18 l of reaction mixture containing 65 mm NaCl, 10 mm HEPES (pH 7.9), 1 mm DTT, 2% Ficoll 400, 4% glycerol, and 1 g of poly(deoxyinosinic-deoxycytidylic acid; Amersham Life Science Inc.) The mixture was preincubated on ice for 15 min followed by addition of 30,000 cpm (1-1.5 ng) of the doublestranded labeled oligonucleotide (high-affinity SIE sequence; Ref. 26 ) and additionally incubated for 30 min at room temperature. Samples were analyzed in a 20 ϫ 20 cm 5% polyacrylamide gel with a bisacrylamide:acrylamide ratio of 1:39 containing 2.5% glycerol and 0.5 ϫ TBE (45 mm Tris base and 1 mm EDTA). Electrophoresis was carried out at 175 V until the faster migrating bromphenol blue dye was ϳ4 cm from the bottom edge. The gel was dried and subjected to autoradiography using KodakXAR5 film for 3 days with intensifying screens at Ϫ70°C.
RESULTS

Expression and Ligand-Induced Phosphorylation of the EGFR in Normal and Immortalized Keratinocytes and in SCCs.
In an earlier study we observed that EGFR activation contributes to STAT3 phosphorylation on Y705 in A431 SCCs but not in immortalized HaCaT keratinocytes (5). These two cell lines were derived from malignant and normal epidermis, respectively. In addition, these cell lines are distinguished by high (A431) and low levels (HaCaT) of EGFR expression. On the basis of these results, we hypothesized that EGFR-dependent STAT3 phosphorylation is restricted to epithelial cells with deregulated EGFR expression and signaling and, hence, a tumor-associated phenomenon. To test this hypothesis we screened a panel of 4 normal primary keratinocytes and 5 malignant SCCs derived either from skin (SCC9, SCC12, and A431) or oral mucosa (all others) for EGFR expression and activation states. For control purposes we included immortalized HaCaT keratinocytes derived from skin (23) . We observed that all of the cell lines tested expressed the EGFR albeit at different levels ( Fig. 1 ). When compared with four primary keratinocyte strains and to immortalized HaCaT keratinocytes, the malignant cell lines (Det562, FaDu, SCC12, SCC9, and A431) expressed higher levels of the EGFR with A431 cells expressing the highest. Next, we tested the EGFR phosphorylation state in these cell lines in the presence and absence of exogenous EGF in chemically defined, serum-free media (22) . Short-term exposure to 10 ng/ml EGF for 15 min induced EGFR phosphorylation in all of the cell lines as determined by immunoprecipitation of the EGFR followed Western blot analysis using a phosphotyrosine-specific antibody (Fig. 1) . The strength of the signal varied with higher levels of EGFR phosphorylation in the transformed cells and the highest level Fig. 1 . Expression and phosphorylation of the epidermal growth factor receptor (EGFR) in normal and transformed keratinocytes. Cell extracts were prepared from the cell lines as indicated after stimulation of growth factor-starved cultures with epidermal growth factor (EGF; 10 ng/ml) for 15 min. EGFR expression and phosphorylation levels were determined using antibodies to the extracellular domain of the EGFR and PY20, respectively, by immunoprecipitation and Western blot analyses. For loading controls please refer to Fig. 2 , which shows expression levels of STAT3 in the same samples.
, and A431) revealed "constitutive" EGFR phosphorylation in the absence of exogenous EGF. In conclusion, the panel of cell lines assembled represents a diverse array of EGFR expression and activation states consistent with deregulated EGFR activation in the malignant cells.
Expression and EGFR-Dependent STAT3 Phosphorylation in Normal and Malignant Keratinocytes. Next, we determined expression and phosphorylation of STAT3 in the panel of cell lines under investigation (Fig. 2) . As determined by Western blot analysis all of the cell lines tested expressed STAT3. Consistent with our earlier results (15) addition of EGF to the culture medium induced robust phosphorylation of STAT3 on Y705 in A431 but not in HaCaT cells. STAT3 tyrosine phosphorylation was not detected in any of the 4 normal keratinocyte strains tested either in the presence or absence of exogenous EGF. By contrast, all of the carcinoma cell lines except Det562 revealed STAT3 Y705 phosphorylation in the presence of exogenous EGF. Interestingly, SCC9, SCC12, and FaDu cell extracts contained phosphorylated STAT3-Y705 also in the absence of exogenous EGF. To assess whether the EGFR was functional in the cell lines under investigation we also determined MAPK phosphorylation in all of the conditions. We had observed previously that MAPK phosphorylation in normal keratinocytes and HaCaT cells strictly correlates with EGFR activation under the experimental conditions chosen (15) . Consistent with these earlier results, all of the cell lines under investigation here responded to EGF treatment with robust MAPK phosphorylation. The comparatively strong phospho-MAPK signal in some of the keratinocyte extracts is likely due to higher protein concentrations in these samples as evidenced by equally higher levels of STAT3 protein in the same samples.
These results raised the issue of whether STAT3 tyrosine phosphorylation seen in the absence of exogenous EGF in SCC lines was due to EGFR activation via autocrine EGFR ligands. To probe the contribution of endogenous EGFR ligands to STAT3 phosphorylation in FaDu, SCC9, SCC12, and A431 cells we used the EGFR antagonistic tyrphostin AG1478 (Fig. 3A) . AG1478 abrogated EGFR phosphorylation (data not shown) and markedly inhibited EGFR-dependent MAPK phosphorylation in all 4 of the SCC lines tested. Yet, AG1478 treatment had only marginal effects on STAT3 phosphorylation in those 3 cell lines that demonstrated STAT3-Y705 phosphorylation in the absence of exogenous EGF. Notably, however, AG1478 inhibited the effect of exogenous EGF on STAT3-Y705 phosphorylation in SCC9 and SCC12 cells, and abrogated STAT3 phosphorylation altogether in A431 cells. To ascertain a potential role of gp130 activation in EGFR-independent STAT3 phosphorylation we used the Janusactivated kinase (JAK) inhibitor AG490 (Fig. 3B) . AG490 had marginal effects on STAT3 phosphorylation in 2 of the 3 cell lines exhibiting EGFR-independent STAT3-Y705 phosphorylation, although it inhibited interleukin 6-induced STAT3 phosphorylation in K562 erythroleukemia cells (Fig. 3C) . A combination of AG1478 and AG490 did not reveal additive effects on EGFR-independent STAT3-Y705 phosphorylation. Furthermore, a triple combination of AG1478/ AG490 and SRC kinase inhibitors (PP1 or PP2) did not significantly affect EGFR-independent steady-state STAT3 phosphorylation (data not shown). Taken together, these results point to the existence of EGFR-dependent and EGFR/JAK-independent pathways that cooperatively induce STAT3 tyrosine phosphorylation in SCCs.
DNA Binding of STAT3 in Normal and Malignant Keratinocytes. To additionally define the effect of EGFR activation on STAT3 activity in SCCs we performed electrophoretic mobility shift assays using oligonucleotides containing a STAT3 DNA binding motif (Fig.  4) . These experiments were done using cell extracts prepared in the presence and absence of exogenous EGF and the EGFR inhibitor AG1478. Only malignant tumor cell extracts produced STAT3:DNA complexes, and this phenomenon was restricted to extracts from EGF-treated cultures. SCC12 cells were a notable exception, because no DNA binding activity was observed either in the presence or absence of exogenous EGF, although these cells showed STAT3-Y705 phosphorylation under these conditions (Fig. 2) . As expected, STAT3:DNA complexes were absent in both HaCaT cells and normal keratinocytes regardless of treatment with EGF. Interestingly, tumor Absence of STAT3 Phosphorylation in HaCaT Cells Overexpressing the EGFR. Next, we asked the question of whether overexpressing the EGFR in HaCaT cells affects STAT3 tyrosine phosphorylation. To this end, we generated HaCaT cells with levels of EGFR expression similar to those observed in SCCs (HaCaT-EGFR; Fig. 5 ). Although EGFR phosphorylation in these cells was markedly higher than in parental HaCaT cells and comparable with those observed in SCC9 or SCC12 cells (Fig. 1) , neither STAT3-Y705 phosphorylation nor DNA binding activity (Fig. 4) was observed in these cells either in the presence or absence of exogenous EGF.
Inhibition of STAT3 Phosphorylation in Normal and Malignant Keratinocytes by EGFR-Dependent MEK Activity. This result raised the issue of whether, in HaCaT keratinocytes, STAT3 tyrosine phosphorylation can be induced by any means. To this end, we first used HaCaT cells conditionally overexpressing a dominant-negative but phosphorylatable STAT3 construct (STAT3D) as described earlier (15, 27) . As shown in Fig. 6A , upon overexpression of STAT3D in HaCaT cells, robust STAT3-Y705 phosphorylation was observed. By contrast and as expected, conditional overexpression of a dominantnegative construct in which Y705 had been replaced by phenylalanine (STAT3F; Ref. 27) did not result in STAT3-Y705 phosphorylation under these conditions. Next, we assessed whether STAT3 expressed at physiological levels could be phosphorylated on Y705 by using the MEK inhibitor U0126 (Fig. 6B) . This was done based on previous reports, which demonstrated that blocking MEK enhances interleukin 6-dependent STAT3 tyrosine phosphorylation in HepG2 hepatoma and MM6 myeloma cells (28, 29) . Consistent with these earlier reports pharmacological inhibition of MEK activity with the U0126 compound was accompanied not only by reduced phosphorylation of MAPK but also by increased STAT3 Y705 phosphorylation in HaCaT cells. Interestingly, this effect was obvious only in the presence of exogenous EGF. Similarly, blocking MEK activity in SCC9, FaDu, SCC12, and A431 cells with U0126 was associated with enhanced levels of STAT3 Y705 phosphorylation in response to exogenous EGF. To ascertain that this effect was due to inhibition of MEK rather than nonspecific effects of U0126, we used HaCaT keratinocytes engineered to express dominant-negative MEK in an inducible fash- Fig. 4 . DNA binding of signal transducer and activator of transcription (STAT)3 in SCC lines. Cell lines were treated with epidermal growth factor (EGF; 10 ng/ml) in the presence and absence of AG1478 (10 M) as indicated. Cell extracts were prepared and subjected to electrophoretic mobility shift assays with 32 P-labeled STAT3-specific probes. The position of protein/DNA complexes is indicated. The nomenclature of the complexes (SIF-A, -B, and -C) refers to the designations given previously (26) . DNA binding activity of STAT3 was restricted to EGF-treated FaDu, SCC9, and A431 cultures. ion as described previously (15) . Induction of the transgene in these cells also led to STAT3-Y705 phosphorylation in a strictly EGFRdependent manner (Fig. 6C ). These results demonstrate that EGFR activation can elicit STAT3 phosphorylation on Y705 in HaCaT cells. However, for this effect to take place concomitant MEK activation needs to be inhibited.
EGFR-Dependent STAT3 Serine Phosphorylation. It has been described previously that EGFR activation leads to phosphorylation of STAT3 on S727 through a MAPK-dependent pathway (28) . Therefore, we assessed patterns of dual phosphorylation of STAT3 on Y705 and S727 in the presence of EGF in SCCs (Fig. 6B) . Because S727 phosphorylation appears to be induced by MAPK in other cell systems we also tested the effect of the MEK inhibitor U0126 on S727 STAT3 phosphorylation. The results of this analysis showed S727 phosphorylation in all of the cell lines in the absence of exogenous EGF. Addition of EGF led to increased S727 phosphorylation in SCC9 and FaDu cells but not in HaCaT, SCC12, or A431 cells. Treatment with U0126 moderately reduced but did not abrogate S727 phosphorylation in HaCaT, SCC9, FaDu, and A431 cells in the presence and absence of exogenous EGF. By contrast, only marginal effects of U0126 were observed in SCC12 cells. These results suggest that STAT3-S727 phosphorylation in SCC lines is, in part, dependent on MEK activity. Yet, no obvious relationship between EGF-dependent STAT3-S727 phosphorylation and DNA binding of STAT3 emerged in the panel of cell lines investigated here. Specifically, in A431 cells, EGF induced robust DNA binding, yet STAT3-S727 phosphorylation was not affected. In addition, comparatively high levels of STAT3-S727 phosphorylation were observed in SCC12 cells, which revealed no STAT3/ DNA binding activity either in the absence or presence of exogenous EGF. We conclude that EGFR phosphorylation is likely to contribute a signal distinct from Y705 and S727 phosphorylation that is necessary to acquire STAT3 DNA binding competence.
DISCUSSION
The present study was designed to test the hypothesis that STAT3 activation is a tumor-associated phenomenon associated with deregulated EGFR signaling in SCCs. Whereas the results obtained strongly support this contention they also raise several unexpected issues about STAT3 activation in normal and malignant keratinocytes. First and foremost we observed that dual STAT3 phosphorylation on Y705 and S727 was not sufficient to induce STAT3 DNA binding in this cell type. These results are reminiscent of a recent study by Bild et al. (30) who demonstrated that, in addition to phosphorylation, endocytotic transport of STAT3, presumably complexed with the activated EGFR, is a necessary prerequisite for nuclear import, DNA binding, and transcriptional activity in NIH3T3 cells engineered to overexpress the EGFR.
Another rather unexpected result of this study related to the presence of pSTAT3-Y705 in growth factor-starved malignant epithelial cells. Furthermore, STAT3-Y705 phosphorylation persisted in these cells in the presence of the EGFR inhibitor AG1478. During preparation of this article a similar observation was reported using a different set of head and neck SCCs (31) . In that report EGFRindependent STAT3-Y705 phosphorylation was ascribed to autocrine interleukin 6/JAK-dependent signaling. Our results provide only limited support for this conclusion, because treatment with the JAK inhibitor AG490 reduced pSTAT3-Y705 content in only one (SCC12) of the three cell lines tested. By contrast, AG490 had no detectable effect on pSTAT3-Y705 content in SCC9 and FaDu cells. Similarly, the kinase responsible for STAT3-Y705 phosphorylation in these SCC cells is not a SRC-like kinase, because SRC inhibitors (PP1/PP2) had only negligible effects on EGFR-independent STAT3Y705 phosphorylation. 3 Thus, we have excluded the three major pathways known to contribute to STAT3 tyrosine phosphorylation, i.e., the EGFR, a SRC-like kinase, and gp130/JAK in the maintenance of STAT3 phosphorylation in the growth factor-starved state of SCC in cell culture. Identification of the kinase responsible for this constitutive STAT3-Y705 phosphorylation awaits future studies.
A third observation of interest relates to the finding that EGFRdependent activation of MEK/MAPK signaling negatively regulates STAT3-Y705 phosphorylation in HaCaT cells and in SCCs. Although this phenomenon has been described before in another cell type (28) , the involvement of MEK in those systems was implied only by using pharmacological MEK inhibitors, which are known to also inhibit other members of the MEK family, for example, MEK5 (32) . By using HaCaT cells conditionally overexpressing dominant-negative MEK we were able to provide independent evidence confirming that EGFR-dependent MEK activation serves to suppress EGFR-dependent STAT3-Y705 phosphorylation in HaCaT cells. Moreover, we used cells expressing physiological levels of STAT3 to make this observation. This experimental detail is of considerable importance, because we observed that forced overexpression of STAT3 led to robust Y705 phosphorylation irrespective of regulatory influences (see Fig.  6A ).
In conclusion, the results of the present study highlight complex regulation of STAT3 activation in SCC lines. Of largest practical import is our finding that STAT3 activation is a tumor-associated phenomenon in this cell system and strictly dependent on EGFR activation. Furthermore, our results illuminate the importance of distinguishing STAT3 phosphorylation events from DNA binding activities. Although STAT3 tyrosine phosphorylation appears to be necessary for biological activity, only DNA binding and subsequent transcriptional effects are likely to contribute to STAT3 function relevant to the malignant phenotype.
